VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ECOR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ECORelectroCore, Inc.
$8.28$69M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

ECOR logoelectroCore, Inc.(ECOR)Earnings, Financials & Key Ratios

ECOR•NASDAQ
$8.28
Price updated Jul 6, 2026
SectorHealthcareIndustryMedical DevicesSub-IndustryNeuromodulation and neuro devices
AboutelectroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.Show more
  • Revenue$32M+27.2%
  • EBITDA-$11M-5.3%
  • Net Income-$14M-17.5%
  • EPS (Diluted)-1.65-3.8%
  • Gross Margin86.75%+2.1%
  • EBITDA Margin-35.83%+17.2%
  • Operating Margin-41.06%+15.0%
  • Net Margin-43.6%+7.6%
  • ROE-478.7%-201.8%

ECOR Price & Volume

electroCore, Inc. (ECOR) stock price & volume — 10-year historical chart

Loading chart...

Revenue Growth Struggles Against Persistent Operating Deficits

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Expanding
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and capital dilution

Key Thesis Takeaways

  • electroCore demonstrates strong top-line momentum with 42.6% year-over-year revenue growth in 2026Q1, yet the company remains fundamentally challenged by an inability to achieve operating leverage as SG&A expenses of $12.9 million continue to dwarf gross profits.
  • The firm's reliance on external debt, which has ballooned to $9.5 million, combined with a negative equity position of $5.7 million, creates a precarious financial profile.
  • Investors should monitor the company's ability to bridge its structural cash burn, as the current $4.9 million cash position provides a limited runway for future operations.

Verdict Logic

the company's reliance on external financing to cover a $5.3 million quarterly operating loss, coupled with a dwindling cash reserve of $4.9 million, presents significant solvency risks for shareholders.

ECOR Growth Metrics

electroCore, Inc. (ECOR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years55.74%
3 Years55.06%
TTM31.9%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-25.72%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-13.84%

Return on Capital

10 Years-115.32%
5 Years-112.07%
3 Years-137.86%
Last Year-141.14%

ECOR Recent Earnings

electroCore, Inc. (ECOR) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 6, 2026
Metric
Actual
Est
EPS
$0.59+0.0%
$0.59
Rev
$10M+6.4%
$9M
Q2 2026
Mar 19, 2026
Metric
Actual
Est
EPS
$0.34+2.9%
$0.35
Rev
$9M+1.5%
$9M
Q4 2025
Nov 5, 2025
Metric
Actual
Est
EPS
$0.40-11.1%
$0.36
Rev
$9M+9.8%
$8M
Q3 2025
Aug 6, 2025
Metric
Actual
Est
EPS
$0.35-9.4%
$0.32
Rev
$7M-5.9%
$8M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 6, 2026
$0.59vs $0.59+0.0%
$10Mvs $9M+6.4%
Q2 2026Mar 19, 2026
$0.34vs $0.35+2.9%
$9Mvs $9M+1.5%
Q4 2025Nov 5, 2025
$0.40vs $0.36-11.1%
$9Mvs $8M+9.8%
Q3 2025Aug 6, 2025
$0.35vs $0.32-9.4%
$7Mvs $8M-5.9%
Based on last 12 quarters of dataView full earnings history →

Latest ECOR News

Recent stock market news and headlines for electroCore, Inc. (ECOR)

Seeking Alpha·Jun 23, 2026
electroCore, Inc. (ECOR) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript

electroCore, Inc. (ECOR) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript

GlobeNewsWire·Jun 17, 2026
electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference

ROCKAWAY, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will participate in the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23-24, 2026.

Peers Comparison

Key metrics vs top competitors for electroCore, Inc. (ECOR)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ECOR logoECORelectroCore, Inc.Current
$8.28$68.69M-5.0227.2%-43.6%-478.7%—
LIVN logoLIVNLivaNova PLC
$84.03$4.62B-18.8810.74%7.47%9.13%—
NVCR logoNVCRNovoCure Limited
$17.32$1.97B-14.208.28%-25.66%-50.82%—
STIM logoSTIMNeuronetics, Inc.
$1.35$93.94M-2.2999.17%-24.48%-139.83%—
ABT logoABTAbbott Laboratories
$95.63$166.57B25.715.67%13.91%12.09%—
MDT logoMDTMedtronic plc
$83.06$106.64B22.278.43%13.2%9.78%—

Compare ECOR vs Peers

electroCore, Inc. (ECOR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs LIVN

Most directly comparable listed peer for ECOR.

Scale Benchmark

vs ABT

Larger-name benchmark to compare ECOR against a more recognizable public peer.

Peer Set

Compare Top 5

vs LIVN, NVCR, STIM, ABT

ECOR SEC Filings & Documents

electroCore, Inc. (ECOR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 6, 2026·SEC

Material company update

Mar 19, 2026·SEC

Material company update

Jan 20, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 19, 2026·SEC

FY 2025

Mar 12, 2025·SEC

FY 2024

Mar 13, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 6, 2026·SEC

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 6, 2025·SEC

Get notified when ECOR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ECOR Frequently Asked Questions

electroCore, Inc. (ECOR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is electroCore, Inc.'s revenue?

electroCore, Inc. (ECOR) reported $34.9M in revenue for fiscal year 2025. This represents a 13632% increase from $0.3M in 2016.

How fast is electroCore, Inc. growing?

electroCore, Inc. (ECOR) grew revenue by 27.2% over the past year. This is strong growth.

Is ECOR profitable?

electroCore, Inc. (ECOR) reported a net loss of $15.4M for fiscal year 2025.

Dividend & Returns
What is ECOR's return on equity?

electroCore, Inc. (ECOR) has a return on equity (ROE) of -478.7%. Negative ROE indicates the company is unprofitable.

What is electroCore, Inc.'s free cash flow?

electroCore, Inc. (ECOR) had negative free cash flow of $6.9M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in ECOR back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →